Sectors

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Miyako Capital has contributed to a series A round for the cancer vaccine developer, which expanded to Japan last year.

The money will fund the progress of the University of London-linked precision medicine developer's lead drug candidate into the clinic.

Google subsidiary Gradient Ventures returned for a $14m second tranche of the round, having led the August 2020 first close.

Konishiyasu and Sojitz contributed to a series A round for the cancer vaccine developer, which expanded to their home of Japan last year.

SoftBank Vision Fund 2, Itochu and an unnamed insurer took part in a series C round that hiked the gene and cell therapy developer's total funding to $845m.

IBM Ventures participated in a $20m round for the neurological disease diagnostics technology developer, a spinout from Tel Aviv University.

The ophthalmic treatment developer has now raised almost $36m in total, with CR-CP Life Science Fund having led a $25m round.

Osaka spinout Cuorips has added $14.7m to its coffers from investors including vehicles for the institution and Kyoto University, just three months after collecting $19.3m.

Autonomous taxi developer Voyage had received a total of $52m from investors including InMotion Ventures and Chevron Technology Ventures.

The database software provider more than doubled its valuation to nearly $5.8bn in a series E round that boosted its cash on hand to about $500m.